<DOC>
	<DOCNO>NCT00041028</DOCNO>
	<brief_summary>RATIONALE : Knowing level oxygen tumor tissue may help predict effectiveness anticancer therapy . EF5 drug use measurement oxygen tumor tissue . PURPOSE : Phase II trial study effectiveness EF5 assess tumor response anticancer therapy patient stage I , stage II , stage III non-small cell lung cancer .</brief_summary>
	<brief_title>EF5 Assessing Tumor Response Anticancer Therapy Patients With Stage I , Stage II , Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess frequency degree hypoxia measure etanidazole derivative EF5 binding patient stage I , II , III non-small cell lung cancer . - Correlate hypoxia measure EF5 bind potential serum/plasma marker tissue marker hypoxia patient . - Correlate hypoxia measure EF5 bind tumor angiogenesis apoptosis patient . - Correlate tumor perfusion hypoxia patient . - Correlate tumor perfusion microvessel density tumor sample patient . - Determine longevity EF5 adduct human lung tumor . OUTLINE : Patients stratify accord disease stage ( stage I II v stage III v stage I-III determine pathologic staging ) . Within 24-48 hour prior plan surgical procedure , patient receive etanidazole derivative EF5 IV 1-2.5 hour . Tumor hypoxia measure use intraoperative Eppendorf needle electrode surgical biopsy resection . Tumor specimen test EF5 bind use immunohistochemistry flow cytometry . Patients follow 4-6 week . PROJECTED ACCRUAL : A total 40-60 patient ( 20 stage I/II disease , 20 stage III disease , 20 without stage I-III disease ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm suspected nonsmall cell lung cancer ( NSCLC ) If histological cytological documentation NSCLC , must least 75 % probability NSCLC Clinical pathological stage IIII Patients presurgical stag definitively establish stage IV disease allow Tumor mass ≥ 1.5 cm maximum diameter must present CT scan must include planned surgical biopsy resection Must planning undergo surgical staging treatment procedure ( include mediastinoscopy , wedge resection , lobectomy , pneumonectomy ) PATIENT CHARACTERISTICS : Age : 18 Performance status : 02 Life expectancy : Not specify Hematopoietic : WBC &gt; 2,000/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic : Bilirubin normal Renal : Creatinine normal OR Creatinine clearance ≥ 60 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month study participation Able hold breath 27 second No allergy IV contrast dye No history grade III IV peripheral neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>